A breakthrough for women living with lipedema: Germany officially recognizes liposuction as a reimbursed treatment.
July 17, 2025 marks a turning point in the recognition of lipedema as a disease requiring appropriate treatment. In Germany, the Federal Joint Committee (G-BA), the equivalent of a national health assessment board, has approved the inclusion of specialized liposuction in the list of publicly covered treatments, regardless of disease stage or severity.
Until now, only a small number of patients with stage III lipedema had limited access to this surgery. Thanks to the positive results of a rigorous pilot study, the G-BA now recognizes that specialized liposuction offers real benefits in reducing pain and improving mobility, compared to conservative treatment alone.
Why is this important for Canada?
This decision sends a strong message to the scientific and medical community: lipedema is a painful, progressive chronic disease that deserves a structured care approach. It also highlights the importance of generating solid evidence to guide reimbursement policies.
In Canada, where liposuction for lipedema is not reimbursed and care pathways remain underdeveloped, this breakthrough could inspire public bodies to support research, structure care delivery, and consider coverage for this treatment. When not properly treated, lipedema can also lead to secondary lymphedema.
For patients, families, and clinicians advocating for lipedema recognition, this announcement confirms that a care model based on science, quality, and equitable access is possible.
Will Canada follow Germany’s lead?
The LAQ and its Lipedema community are committed to helping make it happen.
More details on this milestone and the LIPLEG study will appear in the September–October issue of L’info AQL – the LAQ members’ magazine.
